I also wouldn't mind owning this stock five years from now. As for a takeover, I think there is a poison pill in place but don't know the details and not sure how effective it would be given the large stake the Bakers have.
Sentiment: Strong Buy
That looks interesting (BLCM) although I'm very overweight in biotech mostly because of SGEN. I use j3sg for insider trades. You can have a report emailed daily on all insider transactions.
She's ready to sing "God Bless America." I sold XOMA some time ago. They are not all winners but I wish you well with it. BB are sometimes very speculative. I bought MAST following them and am up 4 cents!
Thanking someone for good info doesn't make me someone else, but I can see how your twisted mind operates. I think you need to delete yourself again.
Ricky, a great way to ask yourself a question with different identities. Maui seems to be a disposable ID that you have deleted at least twice. Now your listed as new as of April 30th. Really slick... Also the continued attempts to drive SGEN down, do you really think anyone listens to you except for laughs? And re SGEN you state "false run ups of these....." Do you really think that is true for SGEN? It has steadily climbed based on scientific evidence and positive clinical trials and will continue to do so. To compare it to some like the CART players who enter the market and overnight go into nosebleed territory is really disingenuous on your part. Your attempts at honest discussion is -well, it's dishonest.
Sentiment: Strong Buy
Truely bizzare posts by the same person And you still seem to have an obsession with the number 10. I need to reasses my ignore policy as you are getting tiresome.
LOL. There are a few people on ignore but I have not (Yet) put any of your multiple personalities on ignore for reasons I myself cannot figure out. As for SGEN I think the immonotherapy aspect is icing on the cake and it comes at a good time since everyone is in love with the concept. They now have two products in that category and with Adcetris so well developed already, they can jump right in with new clinical collaborations.
I'm a buy and hold guy. I'll probably die holding some up and comers. Average $8 with SGEN. Sold enough to more than pay for my investment and will just wait on the rest.
For the first time, data will be presented demonstrating that brentuximab vedotin (ADCETRIS) induces Immunogenic Cell Death (ICD), a pattern of cytotoxicity associated with activating immune responses within the tumor microenvironment. In evaluating CD30-positive Hodgkin lymphoma tumor cell lines treated with brentuximab vedotin, data demonstrate an ER stress response characterized by display of calreticulin and HSP70 on the surface of brentuximab vedotin-treated lymphoma cells and activation of dendritic cells. These data provide rationale for combining brentuximab vedotin with immuno-oncology agents, such as nivolumab, to maximize cancer cell death and provide a favorable environment for immune activation within the tumor milieu. As part of a collaboration between Seattle Genetics and Bristol Myers Squibb, two clinical trials are planned for initiation in 2015 to evaluate brentuximab vedotin in combination with nivolumab in relapsed Hodgkin lymphoma and relapsed CD30-positive non-Hodgkin lymphoma. The poster entitled “Brentuximab vedotin-mediated immunogenic cell death” will be presented on Monday, April 20, 2015 (Abstract #2469).